Phibro (PAHC) Q4 2026 Earnings Call Transcript

Phibro Animal Health reported fiscal 2026 net sales of $1.518B (+17%) and adjusted EBITDA of $255M (+39%), with adjusted diluted EPS up 48% to $3.22. Q4 net sales rose 5% to $396.7M and adjusted EBITDA increased 29% to $64.2M. For fiscal 2027, management guided net sales of $1.55B–$1.60B (midpoint +4%), adjusted EBITDA of $258M–$268M (~+3% at midpoint), and adjusted diluted EPS of $3.41–$3.59, while flagging regulatory uncertainty around Brazil virginiamycin (assumed minimal sales) and a Chicago Heights facility closure (cash one-time costs ~+$10M and ongoing EBITDA benefit ~+$15M–$20M starting FY2028). Free cash flow was $10M in FY2026, constrained by an ~$86.3M inventory build tied to the acquisition, with inventory growth expected to fall to ~$25M–$30M in FY2027 as working capital normalizes.

Analysis

PAHC is transitioning from a transaction/integration story into a cash-conversion story. The market should care more about the implied reset in working capital than the headline EPS growth: if inventory normalizes as guided, free cash flow can inflect sharply even with only low-single-digit EBITDA growth, which supports de-levering and a better equity multiple over the next 2-3 quarters. The flip side is that the earnings quality still looks lumpy: Q1 is set up as a mechanical negative EBIT print, so momentum buyers could be disappointed if they extrapolate the last 12 months too aggressively.

The biggest second-order issue is Brazil. If virginiamycin is restored, the upside is not just the lost revenue; it also improves mix because this is a high-margin SKU that helps absorb corporate overhead. If it stays constrained through the election window, the earnings base is lower than consensus likely thinks and the market may need to re-rate PAHC as a mid-teens EBITDA multiple story rather than a premium growth compounder. The Chicago Heights closure is more important for 2028 than 2027, which means near-term P&L benefit is probably being overstated relative to the real structural margin gain.

Contrarian view: consensus may be underestimating the operating leverage from inventory discipline and the closing of underutilized manufacturing, but it may also be overestimating the durability of reported growth because a chunk of the move is acquisition math plus commodity pass-through. On balance this looks like a modestly positive setup, not a clean breakout catalyst. For a cleaner relative expression, PAHC screens better as a tactical long versus ZTS only if you believe the integration and mix benefits will drive multiple expansion faster than ZTS's steadier but slower growth profile.

Key Decisions for Investors

• Buy PAHC on a post-earnings pullback, targeting a 3-6 month hold: thesis is FCF inflection and leverage reduction rather than top-line acceleration. Falsify if Q1 EBIT stays negative beyond management's guidance or inventory does not step down toward the $25M-$30M build range.
• Pair trade: long PAHC / short ZTS, sized modestly, to express a relative re-rating if PAHC's margin and cash conversion improve faster than the market expects. The risk is that ZTS continues to command a premium multiple for cleaner execution; cut if PAHC loses the Brazil regulatory window.
• For event-driven upside, consider a small PAHC call spread into the October Brazil regulatory window. The payoff is asymmetric because a therapeutic approval would improve mix, but the position should be sized as a binary event trade; exit if no decision emerges by the end of the transition period.
• Avoid chasing the stock into the first Q1 print; wait for evidence that SG&A has normalized and that inventory is not re-accelerating. This is the cleanest place to fade momentum buyers if the market prices in 2028 benefits too early.
• Watch for 2027 capex and cash flow disclosures as the real catalyst. If management shows CapEx peaking while FCF turns meaningfully positive, the stock can support a higher multiple; if CapEx stays elevated without revenue acceleration, this becomes a value trap.